Depression and Anxiety in Rheumatoid Arthritis

Overview

The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs

Full Title of Study: “Depression and Anxiety in Rheumatoid Arthritis: Prevalence and Relation With Disease Activity”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 2015

Detailed Description

The prevalence of anxiety and depressive disorders will be assesed with the HADS questionnaire at the time of the visit

Interventions

  • Other: Hospital Anxiety and Depression Scale (HADS) questionnaire
    • Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire

Arms, Groups and Cohorts

  • Patients RA-BIO
    • Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)

Clinical Trial Outcome Measures

Primary Measures

  • Hospital Anxiety and Depression Scale (HADS)
    • Time Frame: 1 day of enrollement
    • Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.

Participating in This Clinical Trial

Inclusion Criteria

  • age >18 years
  • diagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria
  • being able to compile questionnaire
  • current treatment with biological disease-modifying antirheumatic drug

Exclusion Criteria

  • Current treatment for anxiety or depressive disorder

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pavia
  • Provider of Information About this Clinical Study
    • Principal Investigator: Vittorio Grosso, MD – University of Pavia
  • Overall Official(s)
    • Roberto Caporali, MD, Study Director, University of Pavia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.